LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 102

Search options

  1. Article: Improving BNT162b2 mRNA Vaccine Tolerability without Efficacy Loss by Pidotimod Supplementation.

    Ucciferri, Claudio / Vecchiet, Jacopo / Auricchio, Antonio / Falasca, Katia

    Mediterranean journal of hematology and infectious diseases

    2022  Volume 14, Issue 1, Page(s) e2022023

    Language English
    Publishing date 2022-03-01
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2674750-9
    ISSN 2035-3006
    ISSN 2035-3006
    DOI 10.4084/MJHID.2022.023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Are monoclonal antibodies effective in patients with severe obesity in SARS-CoV-2 infected?

    Ucciferri, Claudio / Moffa, Livia / Moffa, Samanta / Vecchiet, Jacopo / Falasca, Katia

    Immunity, inflammation and disease

    2023  Volume 11, Issue 2, Page(s) e771

    Abstract: It is important to block SARS-CoV-2 infection immediately with early therapies, such as monoclonal antibodies (MonoAbs). Also, several studies show that obesity is associated with a high risk of severe COVID-19 disease. We enrolled 32 SARS-CoV-2 infected ...

    Abstract It is important to block SARS-CoV-2 infection immediately with early therapies, such as monoclonal antibodies (MonoAbs). Also, several studies show that obesity is associated with a high risk of severe COVID-19 disease. We enrolled 32 SARS-CoV-2 infected patients who received MonoAbs, all patients were not vaccinated for SARS-CoV-2, and they received therapy after 7 ± 2 days from the onset of COVID-19 symptoms. In the days following administration, patients followed home therapy with Pidotimod 800 mg bid for 10 days and cholecalciferol 2000 UI for 20 days, prescribed the same day they received MonoAbs therapy. Our study found that there are no differences in the therapeutic response between obese and nonobese patients with SARS-CoV-2 infection undergoing MonoAbs therapy, in fact, none of them underwent hospitalization. Furthermore, the effect of the immunostimulant Pidotimod and cholecalciferol may have contributed to the resolution of COVID-19 symptoms in these patients.
    MeSH term(s) Humans ; Obesity, Morbid ; SARS-CoV-2 ; Antibodies, Monoclonal ; COVID-19 ; Obesity ; Cholecalciferol
    Chemical Substances pidotimod (785363R681) ; Antibodies, Monoclonal ; Cholecalciferol (1C6V77QF41)
    Language English
    Publishing date 2023-02-27
    Publishing country England
    Document type Journal Article
    ZDB-ID 2740382-8
    ISSN 2050-4527 ; 2050-4527
    ISSN (online) 2050-4527
    ISSN 2050-4527
    DOI 10.1002/iid3.771
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: It is Not Always COVID-19: Case Report about an Undiagnosed HIV Man with Dyspnea.

    Pontolillo, Michela / Falasca, Katia / Vecchiet, Jacopo / Ucciferri, Claudio

    Current HIV research

    2021  Volume 19, Issue 6, Page(s) 548–551

    Abstract: Background: The current COVID-19 pandemic has attracted great attention from the medical world. In the past year, there have been reports of missed or delayed treatments for conditions that mimic COVID-19. The main symptoms caused by SARS-CoV-2, such as ...

    Abstract Background: The current COVID-19 pandemic has attracted great attention from the medical world. In the past year, there have been reports of missed or delayed treatments for conditions that mimic COVID-19. The main symptoms caused by SARS-CoV-2, such as fever and cough, belong to different clinical conditions. It is of the utmost importance that the diagnostic thinking used to analyze data and information to reach a COVID-19 diagnosis does not overlook the plethora of different diagnoses related to these symptoms.
    Case report: The aim of this work is to present the clinical case of a patient having unrecognized HIV infection with a 4-week history of fever, cough, and hypoxia. When tests were allowed to highlight HIV-related immunodeficiency status, a CMV assay was performed in order to evaluate opportunistic pneumonia. Through this, diagnosis of HIV combined with CMV pneumonia was made, thus excluding COVID-19 respiratory insufficiency.
    Conclusion: The diagnosis of the two conditions in the COVID-19 era is challenging due to overlapping clinical and radiological features and limitations of current diagnostic assays. This causes clinical implications due to diagnostic delays.
    MeSH term(s) AIDS-Related Opportunistic Infections/diagnosis ; COVID-19 ; COVID-19 Testing ; Cytomegalovirus Infections/diagnosis ; Diagnosis, Differential ; Dyspnea/virology ; HIV Infections/diagnosis ; Humans ; Male ; Middle Aged ; Pneumonia, Viral/diagnosis
    Language English
    Publishing date 2021-09-01
    Publishing country Netherlands
    Document type Case Reports ; Journal Article
    ZDB-ID 2192348-6
    ISSN 1873-4251 ; 1570-162X
    ISSN (online) 1873-4251
    ISSN 1570-162X
    DOI 10.2174/1570162X19666210901134104
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients.

    Ucciferri, Claudio / Barone, Mirko / Vecchiet, Jacopo / Falasca, Katia

    Mediterranean journal of hematology and infectious diseases

    2020  Volume 12, Issue 1, Page(s) e2020048

    Keywords covid19
    Language English
    Publishing date 2020-07-01
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2674750-9
    ISSN 2035-3006
    ISSN 2035-3006
    DOI 10.4084/MJHID.2020.048
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Role of monoclonal antibody drugs in the treatment of COVID-19.

    Ucciferri, Claudio / Vecchiet, Jacopo / Falasca, Katia

    World journal of clinical cases

    2020  Volume 8, Issue 19, Page(s) 4280–4285

    Abstract: Currently clinicians all around the world are experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical presentation of this pathology includes fever, dry cough, fatigue and acute respiratory distress ... ...

    Abstract Currently clinicians all around the world are experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical presentation of this pathology includes fever, dry cough, fatigue and acute respiratory distress syndrome that can lead to death infected patients. Current studies on coronavirus disease 2019 (COVID-19) continue to highlight the urgent need for an effective therapy. Numerous therapeutic strategies have been used until now but, to date, there is no specific effective treatment for SARS-CoV-2 infection. Elevated inflammatory cytokines have been reported in patients with COVID-19. Evidence suggests that elevated cytokine levels, reflecting a hyperinflammatory response secondary to SARS-CoV-2 infection, are responsible for multi-organ damage in patients with COVID-19. For these reason, numerous randomized clinical trials are currently underway to explore the effectiveness of biopharmaceutical drugs, such as, interleukin-1 blockers, interleukin-6 inhibitors, Janus kinase inhibitors, in COVID-19. The aim of the present paper is to briefly summarize the pathogenetic rationale and the state of the art of therapeutic strategy blocking hyperinflammation.
    Keywords covid19
    Language English
    Publishing date 2020-10-20
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2307-8960
    ISSN 2307-8960
    DOI 10.12998/wjcc.v8.i19.4280
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: New Therapeutic Options in Mild Moderate COVID-19 Outpatients.

    Ucciferri, Claudio / Di Gasbarro, Alessandro / Borrelli, Paola / Di Nicola, Marta / Vecchiet, Jacopo / Falasca, Katia

    Microorganisms

    2022  Volume 10, Issue 11

    Abstract: Background: In recent years, the therapeutic options for COVID have significantly improved; however, the therapies are expensive with restricted access to drugs, and expeditious and difficult to manage at home. We investigated the effect of pidotimod in ... ...

    Abstract Background: In recent years, the therapeutic options for COVID have significantly improved; however, the therapies are expensive with restricted access to drugs, and expeditious and difficult to manage at home. We investigated the effect of pidotimod in preventing hospitalization in patients with mild-moderate COVID-19. Methods: A total of 1231 patients between January and June 2021 were screened. A total of 184 patients with mild-moderate COVID-19 were enrolled and divided into two groups: group-A (97) had undergone therapy with pidotimod 800 mg bid for 7−10 days and group-B (87) had other therapies. We excluded those who had undergone complete vaccination course, monoclonal anti-spike/antivirals or the co-administration of pidotimod-steroid. The primary outcome chosen was the emergency room, hospitalization, and deaths for COVID-related causes; the secondary outcome chosen was the duration of COVID-19 illness. Results: A total of 34 patients (18.5%) required hospital treatment, 11 in group-A and 23 in group-B (11.3% vs. 26.4%, p = 0.008). The median disease duration in group-A was 21 days (IQR 17−27) vs. 23 (IQR 20−31) in group-B (p = 0.005). Patients in the pidotimod group had higher SpO2 in the walking test (IQR 96−99% vs. IQR 93−98%, p = 0.01) and a lower need for steroid rescue therapy (11.5% vs. 60.9%, p < 0.001). Conclusions: In the first phase of disease, pidotimod can represent an effective, low-cost, weapon, without restrictions of use, that is able to prevent a second aggressive phase and promote faster virological recovery.
    Language English
    Publishing date 2022-10-27
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2720891-6
    ISSN 2076-2607
    ISSN 2076-2607
    DOI 10.3390/microorganisms10112131
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Molnupiravir as an Early Treatment for COVID-19: A Real Life Study.

    Pontolillo, Michela / Ucciferri, Claudio / Borrelli, Paola / Di Nicola, Marta / Vecchiet, Jacopo / Falasca, Katia

    Pathogens (Basel, Switzerland)

    2022  Volume 11, Issue 10

    Abstract: Objectives: Below we report our experience in the use of molnupiravir, the first antiviral drug against SARS-CoV-2 available to us, in the treatment of patients with COVID-19.: Materials and methods: We enrolled patients diagnosed with COVID-19 and ... ...

    Abstract Objectives: Below we report our experience in the use of molnupiravir, the first antiviral drug against SARS-CoV-2 available to us, in the treatment of patients with COVID-19.
    Materials and methods: We enrolled patients diagnosed with COVID-19 and comorbidities who were candidates for antiviral drug therapy. All patients received molnupiravir (800 mg twice daily). Blood chemistry checks were carried out at T0 and after 7/10 days after starting therapy (T1).
    Results: There were enrolled within the cohort 100 patients. There was 100.0% compliance with the antiviral treatment. No patient required hospitalization due to worsening of respiratory function or the appearance of serious side effects. The median downtime of viral load was ten days (IQR 8.0-13.0), regardless of the type of vaccination received. The patients who had a shorter distance from vaccination more frequently presented vomiting/diarrhea. During baseline and T1 we found significant differences in the median serum concentrations of the main parameters, in particular of platelets, RDW CV, neutrophils and lymphocytes, the eGFR, liver enzymes, as well as of the main inflammatory markers, CRP and Ferritin.
    Conclusion: Participants treated with molnupiravir, albeit in risk categories, demonstrated early clinical improvement, no need for hospitalization, and a low rate of adverse events.
    Language English
    Publishing date 2022-09-29
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2695572-6
    ISSN 2076-0817
    ISSN 2076-0817
    DOI 10.3390/pathogens11101121
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Risk Factors Associated with Poor Outcome in Patients with Infective Endocarditis: An Italian Single-Center Experience.

    Ucciferri, Claudio / Auricchio, Antonio / Cutone, Carmine / Di Gasbarro, Alessandro / Vecchiet, Jacopo / Falasca, Katia

    Infectious disease reports

    2022  Volume 14, Issue 2, Page(s) 213–219

    Abstract: Background: Nowadays, infective endocarditis (IE) is still burdened by a high mortality. In the absence of an adequate prognostic stratification system, it is important to assess new predictors of poor outcomes. The aim of our study is to evaluate which ... ...

    Abstract Background: Nowadays, infective endocarditis (IE) is still burdened by a high mortality. In the absence of an adequate prognostic stratification system, it is important to assess new predictors of poor outcomes. The aim of our study is to evaluate which factors were associated with higher mortality in IE patients. Methods: A retrospective cohort study enrolled patients with an IE diagnosis at the Infectious Diseases Clinic of the University ‘G. D’Annunzio’, Chieti, Italy from January 2013 to December 2019. For each patient, demographic, anamnestic and clinical information, embolic phenomena, laboratory and microbiologic data, treatment, and outcomes were collected and analyzed. A correlation analysis was performed. Results: Sixty-eight patients with EI were studied; among them, the mortality was 17.6%, 20.6%, and 23.5%, intra-hospital, at 1 month from discharge and at 6 months from discharge, respectively. Mortality was significantly correlated with age, estimated glomerular filtration rate, and procalcitonin values when considering either basal values (r = 0.266, p = 0.029), or values at 48−72 h from the start of an antibiotic therapy (r = 0.222; p < 0.05), cerebral embolization for 6-month mortality (r = 0.284; p = 0.019), and inadequate antibiotic therapy (r = 0.232, p < 0.05). Conclusions: Procalcitonin values, at EI diagnosis and at 48−72 h after starting antibiotics, are prognostic factors useful for stratifying patient risk, and for setting up a personalized treatment. Of note, cerebral embolization and an inappropriate empirical treatment were associated with a higher mortality in the short- and long-term.
    Language English
    Publishing date 2022-03-21
    Publishing country Switzerland
    Document type Journal Article
    ISSN 2036-7430
    ISSN 2036-7430
    DOI 10.3390/idr14020026
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: A rare case of acute tubular necrosis tenofovir alafenamide-related.

    Pontolillo, Michela / Piscitani, Luca / Ucciferri, Claudio / Di Liberato, Lorenzo / Bonomini, Mario / Vecchiet, Jacopo

    Clinical nephrology

    2021  Volume 95, Issue 6, Page(s) 350–352

    MeSH term(s) Adenine ; Alanine ; HIV Infections ; Humans ; Necrosis ; Tenofovir/analogs & derivatives
    Chemical Substances Tenofovir (99YXE507IL) ; tenofovir alafenamide (EL9943AG5J) ; Adenine (JAC85A2161) ; Alanine (OF5P57N2ZX)
    Language English
    Publishing date 2021-03-22
    Publishing country Germany
    Document type Case Reports ; Journal Article
    ZDB-ID 185101-9
    ISSN 0301-0430
    ISSN 0301-0430
    DOI 10.5414/CN110377
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Association of inflammatory biomarkers and cardiovascular risk scores in an Italian cohort of HIV positive patient undergoing antiretroviral therapy.

    Claudio, Ucciferri / Antonio, Auricchio / Marcella, Reale / Erica, Costantini / Jacopo, Vecchiet / Katia, Falasca

    Current HIV research

    2022  

    Abstract: Background: Several algorithms have been developed to predict cardiovascular risk (CVR) over time, however none of them seem to be accurate when applied to HIV patients.: Objective: The aim of this study was to assess plasma inflammatory biomarkers ... ...

    Abstract Background: Several algorithms have been developed to predict cardiovascular risk (CVR) over time, however none of them seem to be accurate when applied to HIV patients.
    Objective: The aim of this study was to assess plasma inflammatory biomarkers in relation to multiple CVR scores (FRS, ASCVD, PROCAM and the DAD-5 Years-Estimated-Risk) in an Italian cohort of HIV patients undergoing a combined Antiretroviral Therapy (cART).
    Methods: We enrolled HIV patients undergoing cART without any change in the HIV-related pharmacological therapy over the last 48 weeks Demographic and anamnestic data were collected, and a biochemical panel including the following biomarkers was collected: CRP, Cystatin-C, microalbuminuria, IL-18, IL-2, IL-4, IL-6, IL-10, TNF-α and IFN- γ. CVR scores were obtained for each patient and compared to the biochemical panel to assess statistical correlation.
    Results: 90 Caucasian HIV patients were enrolled. Assessment of CVR scores showed FRS values of 6.98±6.11%, ASCVD 7.18±6.25%, PROCAM 6.7±7.4% and DAD-5 Years Estimated Risk 3.10±3.41%. We found correlations between the levels of circulating cytokines measured and the cardiovascular risk prediction scores.
    Conclusions: Our data showed that the values of selected inflammatory biomarkers strongly correlate with the CVR scores, suggesting that they can be employed as reliable predictors of cardiovascular disease in HIV patients. The routine use of selected biomarkers associated with systemic inflammation could be a valid and readily available tool for clinicians to assess and monitor cardiovascular risk in HIV patients.

    .
    Language English
    Publishing date 2022-06-23
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2192348-6
    ISSN 1873-4251 ; 1570-162X
    ISSN (online) 1873-4251
    ISSN 1570-162X
    DOI 10.2174/1570162X2002220623163705
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top